Compare Royalty Pharma plc Class A Ordinary Shares (RPRX) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Royalty Pharma plc Class A Ordinary Shares vs GeneDx Holdings Corp — how do they compare? Royalty Pharma plc Class A Ordinary Shares trades at $56.92 (market cap $25.27B), while GeneDx Holdings Corp trades at $67.82 (market cap $2.02B). The key difference: Royalty Pharma plc Class A Ordinary Shares is far larger — about 12.5× GeneDx Holdings Corp's market cap, and Royalty Pharma plc Class A Ordinary Shares pays a 1.66% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Royalty Pharma plc Class A Ordinary Shares for 0 Days and GeneDx Holdings Corp for 19 Days on average.
| RPRX | WGS | |
|---|---|---|
Market Cap | $25.27B | $2.02B |
Volume | 3,671,183 | 734,640 |
Sector | Health | Health |
52-Week High | $63.96 | $167.51 |
52-Week Low | $35.44 | $34.51 |
Typical Hold Time | 0 Days | 19 Days |
Enterprise Value | $32.50B | $2.05B |
Dividend Yield | 1.66% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
GeneDx (WGS) trades at $68.50, down 0.04% with a bearish technical signal despite bullish oscillators showing oversold conditions. The company reported mixed Q2 2026 results with revenue of $114.4M beating expectations but net income margin remains negative at -23.4%. Recent developments include new product launches and positive analyst coverage with 91% buy ratings.
While analyst consensus targets $81.00 (18% upside), fundamental challenges persist with negative profitability metrics and high valuation multiples. The stock faces execution risks amid competitive genomics landscape, but operational improvements and testing volume growth provide potential catalysts for recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Royalty Pharma plc Class A Ordinary Shares
Royalty Pharma acquires interests in royalties from biopharmaceutical products. Its model gives it exposure to medicines developed and sold by other life sciences companies.
Read more on RPRX →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
